Sugi Predict

Sugi Predict / Compounds / SCHEMBL1033969

SCHEMBL1033969

SCHEMBL1033969

O=[N+]([O-])c1cnc2ccccc2c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.51
▸ S100A4 P26447 1/20 0.49
▸ MEN1 O00255 8/20 0.47
▸ KMT2A Q03164 8/20 0.47
▸ MAPT P10636 6/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ CTSB P07858 3/20 0.47
▸ IDO1 P14902 2/20 0.47
▸ TDO2 P48775 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ CASP6 P55212 3/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ GPR35 Q9HC97 1/20 0.46
▸ LMNA P02545 5/20 0.44
▸ HTT P42858 5/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ TDP1 Q9NUW8 4/20 0.44
▸ HSP90AA1 P07900 2/20 0.44
▸ OPRK1 P41145 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16512769 0.81 CASP6 (0.50) S100A4MEN1KMT2AMAPTALDH1A1
SCHEMBL8561101 0.81 POLB (0.53) POLBS100A4MEN1KMT2AMAPT
SCHEMBL2248311 0.81 CRHBP (0.53) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL3865236 0.81 CRHBP (0.53) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL28946141 0.80 MAPT (0.42) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL4727431 0.79 POLB (0.51) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL202663 0.79 POLB (0.51) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL29381779 0.79 POLB (0.51) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL202880 0.79 POLB (0.51) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL15824026 0.79 POLB (0.51) POLBMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114534694-B Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2024-08-16 — — CN claimed
CN-114534694-A Hydroxyquinoline filler and preparation method and application thereof 万华化学集团股份有限公司 2022-05-27 — — CN claimed
CN-110693850-A Preparation method of imiquimod chitosan nanoparticles 湖北科益药业股份有限公司 2020-01-17 — — CN claimed
CN-108003153-A Nitrogenous five-ring heterocycles and quinolines and its salt, preparation method, pharmaceutical composition and purposes 中国医学科学院肿瘤医院 2018-05-08 — — CN claimed
CN-104402878-A Preparation method of imiquimod TIANFANG PHARMACEUTICAL CO LTD 2015-03-11 — — CN claimed
JP-3027380-A — — None — — JP disclosed
JP-3027381-A — — None — — JP disclosed
JP-11269177-A — — None — — JP disclosed
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG, KARA ANN 2026-01-29 — — US disclosed
US-20250262309-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG, KARA ANN 2025-08-21 — — US disclosed
WO-2025103490-A1 N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY Beijing Changping Laboratory (CN) 2025-05-22 — — WO disclosed
CN-119546341-A Proteolytic targeting chimeric (PROTAC) compositions using ubiquitin conjugated enzyme ligands 布普格生物制药公司 2025-02-28 — — CN disclosed
EP-0145340-B1 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1990-01-24 — — EP disclosed
EP-0335274-A2 Formation of nitrophenyl ethers from polyols and nitroanisoles THE DOW CHEMICAL COMPANY (US) 1989-10-04 — — EP disclosed
EP-0310950-A1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1989-04-12 — — EP disclosed
US-4753951-A ANTIDEPRESSANTS, ANXIOLYTICS SHIONOGI & CO., LTD. (JP) 1988-06-28 — — US disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 — — US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 — — US disclosed
EP-0223420-A1 Condensed imidazopyridine derivatives SHIONOGI & CO., LTD. (JP) 1987-05-27 — — EP disclosed
EP-0145340-A2 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1985-06-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250262309-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS UBE3C, UBE3A, MDM2 POLB 3246/4885S100A4 4291/4885MEN1 4190/4885
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS UBE2T, UBE3C, UBE2E1 POLB 2762/4885S100A4 4100/4885MEN1 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.